ASX ANNOUNCEMENT **27 APRIL 2026**

CHM CORE-NK PHASE 1B CLINICAL TRIAL ACHIEVES 60% CR/CRi

- **Of 25 patients now enrolled, 60% have demonstrated complete responses (CR/CRi)**
- **The study is enrolling high-risk, frontline subjects to be treated with CHM CORE-NK in combination with the current standard of care**
- **The treatment is well tolerated & safety remains unchanged in these high risk patients**

Sydney, Australia, 27 April 2026: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce new clinical data from the ADVENT-AML NCT05834244 clinical trial, with 60% of 25 patients enrolled achieving a CR/CRi (Complete Response/Complete response incomplete count recovery).

CR/CRi refers to remission statuses in blood cancer, specifically acute myeloid leukemia (AML):

- **CR,** Complete Response – indicates no detectable leukemia and fully recovered blood counts
- **CRi**, Complete Response with Incomplete count recovery – indicates no detectable leukemia but low platelets (<100,000/μL) or neutrophils (<1000/μL).

The frontline cohort continues to enrol high risk patients at The University of Texas MD Anderson Cancer Center**.** There have been no unexpected safety findings in this group of patients and the combination of CHM CORE-NK with azacitadine and venatoclax continues to be well-tolerated by patients. Current standard of care for these high risk patients typically results in a 20-30% response rate.[1]

Translational data, such as persistence and cytokine profiles, are currently being evaluated.

"As pioneers in cell therapy, these results are a step forward to change the standard of care for high risk AML patients. This is uncharted territory as the world's first frontline cell therapy trial, and we would like to thank to our partners MD Anderson for their efforts in executing on this study," said Dr Rebecca McQualter CEO of Chimeric Thereapeutics.

The ADVENT-AML (NCT05834244) Phase 1B clinical trial is an investigator-initiated study currently open to enrollment at MD Anderson Cancer Center under Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia. Investigator-initiated trials are clinical research studies conceived, designed, and managed by independent researchers (clinicians/academics) rather than biotechnology companies. This study is evaluating the synergy of NK cell therapy in combination with the current standard of care, Azacitidine and Venetoclax.

ADVENT-AML is the first clinical trial to evaluate the synergy of CHM CORE-NK in combination with the current standard of care for AML patients in the frontline setting. The study is now open to enroll up to 3 more subjects with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant.

The CHM CORE-NK cells used in the ADVENT-AML clinical trial were manufactured and cryopreserved for "off-the-shelf" accessibility at the Cellular Therapy Integrated Services Laboratory at Case Western Reserve University, where the CORE-NK technology was developed.

1.Kantarjian HM, Short NJ, Fathi AT, Marcucci G, Ravandi F, Tallman M, Wang ES, Wei AH. Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):580-597. doi: 10.1016/j.clml.2021.05.016. Epub 2021 May 29. PMID: 34176779; PMCID: PMC11938811.

https://clinicaltrials.gov/study/NCT05834244

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of Directors

Contact
Investors
Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au